Journal
ONCOTARGET
Volume 8, Issue 18, Pages 30524-30538Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.15496
Keywords
prostate cancer; photodynamic therapy; photosensitizers
Categories
Funding
- University of Illinois College of Medicine at Rockford
- Brovember Inc., Rockford, IL
Ask authors/readers for more resources
The search for new therapeutics for the treatment of prostate cancer is ongoing with a focus on the balance between the harms and benefits of treatment. New therapies are being constantly developed to offer treatments similar to radical therapies, with limited side effects. Photodynamic therapy (PDT) is a promising strategy in delivering focal treatment in primary as well as post radiotherapy prostate cancer. PDT involves activation of a photosensitizer (PS) by appropriate wavelength of light, generating transient levels of reactive oxygen species (ROS). Several photosensitizers have been developed with a focus on treating prostate cancer like mTHPC, motexafin lutetium, padoporfin and so on. This article will review newly developed photosensitizers under clinical trials for the treatment of prostate cancer, along with the potential advantages and disadvantages in delivering focal therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available